

Interface and Formulary Update - Issue 32 – September and October 2024

Key messages from **September and October 2024 TAG meetings** (ratified by Medicines Optimisation Programme Board)

Commissioning Review Oral Ivermectin for use in scabies	<ul style="list-style-type: none"> ADVICE - Specialist advice required from primary or secondary care clinician with relevant expertise prior to primary care initiation Option for use if topical preparations have not been effective as per NICE CKS
Commissioning Review Tirzepatide for weight management	<ul style="list-style-type: none"> BLACK – not commissioned. Not for prescribing in primary or secondary care Further local guidance found here
Commissioning Review Vacuum dressings for healing of chronic wounds	<ul style="list-style-type: none"> BLACK – not commissioned. Not for prescribing in primary or secondary care
Commissioning Review Xonvea 10mg/10mg gastro-resistant tablets Doxylamine/pyridoxine for nausea and vomiting in pregnancy (to be use as the last management option)	<ul style="list-style-type: none"> ADVICE – third line option, only to be initiated in hospital. Can continue in primary care once patient is stable and treatment has been proven to be effective. Not to be initiated in primary care
Commissioning Review Cholesterol and simvastatin cream for disseminated superficial actinic porokeratosis	<ul style="list-style-type: none"> BLACK – not commissioned. Not for prescribing in primary or secondary care
Commissioning Review HidraWear underwear	<ul style="list-style-type: none"> BLACK – not commissioned. Not for prescribing in primary or secondary care Patients should be advised to purchase
Commissioning Review Bupropion for mental health conditions	<ul style="list-style-type: none"> BLACK – not commissioned. Not for prescribing in primary or secondary care
Commissioning Review Geko wound therapy for reducing the risk of venous thromboembolism	<ul style="list-style-type: none"> BLACK – Not Commissioned. No prescribing in primary or secondary care pending formulary application
Commissioning Review APOS Therapy for knee osteoarthritis	<ul style="list-style-type: none"> BLUE - NWICB are committed to fund positive NICE TA treatments. Awaiting clarification of place in pathway and commissioning arrangements. Further guidance will be issued when available
Commissioning Review Local availability of sleep apps in relation to prescribing of Daridorexant	<ul style="list-style-type: none"> Daridorexant status to remain unchanged Awaiting update on local availability of sleep apps GREEN – Drugs that can be initiated in primary care “only after use of CBTi as per criteria in NICE TA”
<ul style="list-style-type: none"> Local availability of Sleepio and Sleepstation currently under review 	

<p>Formulary Application</p> <p>Esomeprazole 10mg gastro-resistant granules sachets for children with an NG or PEG tube who are ≥1 year old AND ≥10kg</p>	<ul style="list-style-type: none"> GREEN - Drugs that can be initiated in primary care. RESTRICTED TO THOSE WITH NG/PEG 1 YEAR AND ABOVE, AND GREATER THAN 10KG
<p>Formulary Application</p> <p>Finerenone tablets (Kerendia®) for patients with Type 2 diabetes and in stages 3 and 4 chronic kidney disease with albuminuria</p>	<ul style="list-style-type: none"> GREEN – Drugs that can be initiated in primary care
<p>Formulary Application</p> <p>Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy as per TA758</p>	<ul style="list-style-type: none"> RED / HOSPITAL - Prescribing to remain with the hospital or specialist service. No prescribing in primary care Only to be initiated by specialist sleep centre in Cambridge. Not to be initiated in Norfolk and Waveney
<p>Formulary Application</p> <p>Romosozumab for severe osteoporosis in postmenopausal women at high risk of fracture in line with NICE TA791</p>	<ul style="list-style-type: none"> RED / HOSPITAL - Prescribing to remain with the hospital or specialist service. No prescribing in primary care All requests must be approved by ERBON regional MDT (East Anglian Rare Bone Network)

Shared Care Updates

<p>Narcolepsy documents from Cambridge and Peterborough</p> <ul style="list-style-type: none"> Dexamfetamine Methylphenidate Modafinil <p>These new shared care agreements will be Level 1 Only to be initiated by specialist sleep centre in Cambridge. Not to be initiated in Norfolk and Waveney</p>
<p>Adult ADHD – SCA amended to Level 1 to ensure consistency with the narcolepsy documents above</p>
<p>Use of Darbepoetin Alfa for the treatment of anaemia in chronic kidney disease AND unable to attend specialist centre</p>

Traffic Light Additions / Updates (to be read in conjunction with [TAG Agreement document](#))

Hospital	TA986 – July 2024 - Lebrikizumab (Ebglyss®) for treating moderate to severe atopic dermatitis in people 12 years and over
	TA990 – July 2024 - Tenecteplase (Metalyse®) for treating acute ischaemic stroke
	TA998 – August 2024 - Risankizumab (Skyrizi®) for treating moderately to severely active ulcerative colitis
	TA688 – March 2021, updated July 2024 - Selective internal radiation therapies for treating hepatocellular carcinoma
	TA985 – July 2024 - Selective internal radiation therapy with QuiremSpheres for treating unresectable advanced hepatocellular carcinoma
	TA988 – July 2024 - Ivacaftor–tezacaftor–elexacaftor ((IVA–TEZ–ELX; Kaftrio, Vertex®), tezacaftor–ivacaftor (TEZ–IVA; Symkevi, Vertex®) and lumacaftor–ivacaftor (LUM–IVA; Orkambi, Vertex®) for treating cystic fibrosis
	TA989 – July 2024 - Etranacogene dezaparvovec (Hemgenix®) for treating moderately severe or severe haemophilia B
	TA993 – August 2024 - Burosumab (Crysvita®) for treating X-linked hypophosphataemia in adults
	TA995 – August 2024 - Relugolix (Orgovyx®) for treating hormone-sensitive prostate cancer
	TA999 – September 2024 - Vibegron (Obgemsa®) for treating symptoms of overactive bladder syndrome

	TA1004 – September 2024 - Faricimab (Vabysmo®) for treating visual impairment caused by macular oedema after retinal vein occlusion
	TA737 – October 2021, updated August 2024 - Pembrolizumab (Keytruda®) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancer
	TA997 - August 2024 - Pembrolizumab (Keytruda®) with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinoma
	TA1000 – September 2024 - Iptacopan (Fabhalta®) for treating paroxysmal nocturnal haemoglobinuria
	TA1001 – September 2024 - Zanubrutinib (Brukinsa®) for treating marginal zone lymphoma after anti-CD20-based treatment
	TA1002 – September 2024 - Evinacumab (Evkeeza®) for treating homozygous familial hypercholesterolaemia in people 12 years and over
	TA1003 – September 2024 - Exagamglogene autotemcel (Casgevy®) for treating transfusion-dependent beta-thalassaemia in people 12 years and over
	TA1005 – September 2024 - Futibatinib (Lytgobi®) for previously treated advanced cholangiocarcinoma with FGFR2 fusion or rearrangement
	TA1007 – September 2024 - Rucaparib (Rubraca®) for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer (Replaces TA611)
	TA1008 – September 2024 - Trifluridine–tipiracil (Lonsurf®) with bevacizumab for treating metastatic colorectal cancer after 2 systemic treatments
	HST8 – October 2018, updated September 2024 - Burosumab (Crysvita®) for treating X-linked hypophosphataemia in children and young people
BLUE	TA991 – August 2024 - Abaloparatide (Eladynos®) for treating osteoporosis after menopause
	TA996 – August 2024 - Linzagolix (Yselty®) for treating moderate to severe symptoms of uterine fibroids
BLACK	TA992 – July 2024 - Trastuzumab deruxtecan (Enhertu®) for treating HER2-low metastatic or unresectable breast cancer after chemotherapy
	TA987 – July 2024 - Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma
	TA994 – August 2024 - Enzalutamide for treating non-metastatic prostate cancer after radical prostatectomy or radiotherapy
	TA1006 – September 2024 - Empagliflozin for treating type 2 diabetes in people 10 to 17 years (terminated appraisal)

Formulary and Guidance Updates

Formulary Amendments

- **Lotacryn (Latanoprost 50 micrograms/ml 2.5ml Preservative Free Multidose - **ADVICE - Specialist advice required prior to primary care initiation****

Updates to product licences for information:

- **Benilexa** one handed intra-uterine system now has an 8-year contraception licence
- **Levosert** IUS also received an 8 year contraception extension

Guidance Updates

- [PKU Guidance](#)
- [Vitamin D](#) for care home residents
- [Care Home](#) Best Practice Guidance
 - [Expiry of Medication](#)
 - [Oxygen](#)
 - [Lithium](#)
- [Multivitamin and Mineral Supplementation and Monitoring following Bariatric Surgery](#): Guidance for Primary Care
- [Patient Information Leaflet](#) - planning for privately funded bariatric (weight loss) surgery in the UK or abroad
- [Patient Information Leaflet](#) – Over the Counter Multivitamins and Minerals Post NHS Bariatric Surgery
- [Use of Pulmicort Respules \(oral viscous budesonide\)](#) for eosinophilic oesophagitis in paediatrics'
- [Medicines Governance and Local Formulary Decisions](#)

- Asthma Updates:
 - [Asthma Inhaler Types and Devices](#) Oct 2024
 - [Maintenance and Reliever Therapy](#) (MART) Norfolk and Waveney Guidance
 - [Best Value Inhalers](#) for Asthma

Useful Information

Next TAG meeting	Wednesday 4th December 2024
Deadline for agenda submissions	Tuesday 26th November 2024
Netformulary	Norfolk and Waveney Formulary (norfolkandwaveneyformulary.nhs.uk)
Knowledge NoW – Medicines Optimisation Home Page	Prescribing, Pharmacy and Medicines Optimisation - Knowledge NoW (nwknowledgenow.nhs.uk)
TAG Guidance	Therapeutic Advisory Group (TAG) and Commissioning - Knowledge NoW (nwknowledgenow.nhs.uk)
Shared Care Agreements	Shared Care Agreements - Knowledge NoW (nwknowledgenow.nhs.uk)
Pathways and Prescribing Guidance	Pathways and Prescribing Guidance - Knowledge NoW (nwknowledgenow.nhs.uk)
Practice Support	Practice Support - Knowledge NoW (nwknowledgenow.nhs.uk)
Useful Links	Useful Links - Knowledge NoW (nwknowledgenow.nhs.uk)

- Please remember to check both [KNoW](#) and [Netformulary](#) for regular formulary updates
- If you have any interface or formulary queries, please send to the inbox - nwicb.medsqueries@nhs.net